Guofeng Chen
Impact in
- Hepatology top 5%
- Hepatitis C virus research
- Infectious Diseases top 5%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
Papers in
- Epidemiology 12
- Hepatitis B Virus Studies 10
- Liver Disease Diagnosis and Treatment 3
- Surgery 10
- Cholangiocarcinoma and Gallbladder Cancer Studies 3
- Esophageal Cancer Research and Treatment 3
- Co-authors
- Dong Ji (10 shared papers)George Lau (4 shared papers)Xiaoli Jin (13 shared papers)Yu Wang (2 shared papers)Chen Zhu (1 shared paper)Jingfeng Bi (1 shared paper)Dawei Zhang (1 shared paper)Jing Xu (1 shared paper)
- Journals
- Hepatology International (3 papers)PLoS ONE (2 papers)Nature Communications (2 papers)Medicine (2 papers)Translational Oncology (2 papers)
- Partner nations
- ChinaUnited StatesGermany
In The Last Decade
Guofeng Chen
64 papers receiving 1.3k citations
Peers
Comparison fields: 5 of 119
- Hepatology 222
- Infectious Diseases 250
- Epidemiology 326
- Health Informatics 8
- Neurology 80
Countries citing papers authored by Guofeng Chen
This map shows the geographic impact of Guofeng Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guofeng Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guofeng Chen more than expected).
Fields of papers citing papers by Guofeng Chen
This network shows the impact of papers produced by Guofeng Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guofeng Chen. The network helps show where Guofeng Chen may publish in the future.
Co-authors
The 25 scholars most cited alongside Guofeng Chen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 68 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 395 | |
| 2 | 2017 | 106 | |
| 3 | 2007 | 78 | |
| 4 | 2020 | 65 | |
| 5 | 2014 | 61 | |
| 6 | 2020 | 44 | |
| 7 | 2018 | 43 | |
| 8 | 2019 | 42 | |
| 9 | 2021 | 38 | |
| 10 | Patients' attitudes to the use of placebos: results from a New Zealand survey. | 2009 | 35 |
| 11 | 2020 | 31 | |
| 12 | 2012 | 31 | |
| 13 | 1999 | 28 | |
| 14 | 2021 | 27 | |
| 15 | 2019 | 19 | |
| 16 | 2015 | 18 | |
| 17 | 2016 | 14 | |
| 18 | 2023 | 14 | |
| 19 | 2022 | 14 | |
| 20 | 2010 | 13 |
About Guofeng Chen
Guofeng Chen is a scholar working on Epidemiology, Surgery, Hepatology, Molecular Biology and Pulmonary and Respiratory Medicine, having authored 68 papers that have together received 1.3k indexed citations. Recurring topics across this work include Hepatitis B Virus Studies (10 papers), Hepatitis C virus research (6 papers), Acute Myeloid Leukemia Research (4 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (3 papers), Gastric Cancer Management and Outcomes (3 papers), Liver Disease Diagnosis and Treatment (3 papers), Esophageal Cancer Research and Treatment (3 papers) and Ubiquitin and proteasome pathways (2 papers). The work is most often cited by research in Hepatology (222 citations), Infectious Diseases (250 citations), Epidemiology (326 citations), Health Informatics (8 citations) and Neurology (80 citations). Guofeng Chen has collaborated with scholars based in China, United States and Germany. Frequent co-authors include Dong Ji, George Lau, Xiaoli Jin, Yu Wang, Chen Zhu, Jingfeng Bi, Dawei Zhang, Jing Xu, Enqiang Qin and Gregory Cheng. Their work appears in journals such as Hepatology International, PLoS ONE, Nature Communications, Medicine and Translational Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.